EV Biologics Corp, announced that it has closed a $500,000 interest-free loan from a related party. This funding will provide for further development of exosome - and other nanoparticle-enriched biological products, as well as optimization of their scalable, cGMP-compatible, biomanufacturing process. The funds will be also used for comprehensive product analysis by several leading independent laboratories.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6221 USD | +3.32% | +3.32% | -37.79% |
2023 | EV Biologics, Inc. Closes A $500,000 Interest-Free Loan | CI |
2023 | Ev Biologics Completes Production of Cutting-Edge Msc Exosome-Based Therapeutic | CI |
1st Jan change | Capi. | |
---|---|---|
-37.79% | 6.36M | |
+19.57% | 48.69B | |
-5.20% | 15.47B | |
+1.44% | 15.9B | |
-14.21% | 10.44B | |
+27.35% | 8.9B | |
+105.28% | 8.12B | |
+4.79% | 8.38B | |
-7.17% | 7.48B | |
+24.55% | 6.8B |
- Stock Market
- Equities
- YECO Stock
- News EV Biologics, Inc.
- EV Biologics, Inc. Closes A $500,000 Interest-Free Loan